Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma

BMC Cancer

Research

Cheng Zhang¹  Yifu Liu¹  Zhenhao Zeng¹  Heng Yang¹  Xiaochen Zhou¹  Xiaofeng Cheng¹  Yujun Chen¹  Gongxian Wang¹ 

[1] Department of Urology, Jiangxi Province, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, 330000, Nanchang City, People’s Republic of China;Jiangxi Institute of Urology, Nanchang City, 330000, Jiangxi Province, China;

关键词: Cuproptosis;    LncRNA;    Prostate carcinoma;    Prognostic signature;    Machine learning;   

DOI  :  10.1186/s12885-023-10584-0

 received in 2022-11-22, accepted in 2023-01-25,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundCuproptosis, an emerging form of programmed cell death, has recently been identified. However, the association between cuproptosis-related long non-coding RNA (lncRNA) signature and the prognosis in prostate carcinoma remains elusive. This study aims to develop the novel cuproptosis-related lncRNA signature in prostate cancer and explore its latent molecular function.MethodsRNA-seq data and clinical information were downloaded from the TCGA datasets. Then, cuproptosis-related gene was identified from the previous literature and further applied to screen the cuproptosis-related differentially expressed lncRNAs. Patients were randomly assigned to the training cohort or the validation cohort with a 1:1 ratio. Subsequently, the machine learning algorithms (Lasso and stepwise Cox (direction = both)) were used to construct a novel prognostic signature in the training cohorts, which was validated by the validation and the entire TCGA cohorts. The nomogram base on the lncRNA signature and several clinicopathological traits were constructed to predict the prognosis. Functional enrichment and immune analysis were performed to evaluate its potential mechanism. Furthermore, differences in the landscape of gene mutation, tumour mutational burden (TMB), microsatellite instability (MSI), drug sensitivity between both risk groups were also assessed to explicit their relationships.ResultsThe cuproptosis-related lncRNA signature was constructed based on the differentially expressed cuproptosis-related lncRNAs, including AC005790.1, AC011472.4, AC099791.2, AC144450.1, LIPE-AS1, and STPG3-AS1. Kaplan–Meier survival and ROC curves demonstrate that the prognosis signature as an independent risk indicator had excellent potential to predict the prognosis in prostate cancer. The signature was closely associated with age, T stage, N stage, and the Gleason score. Immune analysis shows that the high-risk group was in an immunosuppressive microenvironment. Additionally, the significant difference in landscape of gene mutation, tumour mutational burden, microsatellite instability, and drug sensitivity between both risk groups was observed.ConclusionsA novel cuproptosis-related lncRNA signature was constructed using machine learning algorithms to predict the prognosis of prostate cancer. It was closely with associated with several common clinical traits, immune cell infiltration, immune-related functions, immune checkpoints, gene mutation, TMB, MSI, and the drug sensitivity, which may be useful to improve the clinical outcome.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq226.gif

41116_2022_35_Article_IEq225.gif

41116_2022_35_Article_IEq223.gif

41116_2022_35_Article_IEq216.gif

41116_2022_35_Article_IEq206.gif

41116_2022_35_Article_IEq199.gif

41116_2022_35_Article_IEq194.gif

41116_2022_35_Article_IEq189.gif

41116_2022_35_Article_IEq180.gif

41116_2022_35_Article_IEq162.gif

41116_2022_35_Article_IEq155.gif

41116_2022_35_Article_IEq116.gif

Fig. 1